These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34232521)

  • 1. N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.
    Singh Y; Fuloria NK; Fuloria S; Subramaniyan V; Meenakshi DU; Chakravarthi S; Kumari U; Joshi N; Gupta G
    J Med Virol; 2021 Oct; 93(10):5726-5728. PubMed ID: 34232521
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How 'killer' T cells could boost COVID immunity in face of new variants.
    Ledford H
    Nature; 2021 Feb; 590(7846):374-375. PubMed ID: 33580217
    [No Abstract]   [Full Text] [Related]  

  • 4. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging plasticity of SARS-CoV-2.
    McCormick KD; Jacobs JL; Mellors JW
    Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
    [No Abstract]   [Full Text] [Related]  

  • 9. What the Omicron wave is revealing about human immunity.
    Willyard C
    Nature; 2022 Feb; 602(7895):22-25. PubMed ID: 35110764
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
    Chen Y; Shen H; Huang R; Tong X; Wu C
    Lancet Infect Dis; 2021 Aug; 21(8):1071-1072. PubMed ID: 34051887
    [No Abstract]   [Full Text] [Related]  

  • 11. The great escape? SARS-CoV-2 variants evading neutralizing responses.
    Prévost J; Finzi A
    Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
    Focosi D; Maggi F
    Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
    Volkan E
    Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Activity of BNT162b2-Elicited Serum.
    Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
    N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
    [No Abstract]   [Full Text] [Related]  

  • 16. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
    [No Abstract]   [Full Text] [Related]  

  • 18. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
    Liu L; Iketani S; Guo Y; Chan JF; Wang M; Liu L; Luo Y; Chu H; Huang Y; Nair MS; Yu J; Chik KK; Yuen TT; Yoon C; To KK; Chen H; Yin MT; Sobieszczyk ME; Huang Y; Wang HH; Sheng Z; Yuen KY; Ho DD
    Nature; 2022 Feb; 602(7898):676-681. PubMed ID: 35016198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency.
    Arora P; Rocha C; Kempf A; Nehlmeier I; Graichen L; Winkler MS; Lier M; Schulz S; Jäck HM; Cossmann A; Stankov MV; Behrens GMN; Pöhlmann S; Hoffmann M
    Cell Mol Immunol; 2021 Dec; 18(12):2673-2675. PubMed ID: 34697413
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
    Jiang S; Zhang X; Du L
    Expert Opin Ther Targets; 2021 Jun; 25(6):415-421. PubMed ID: 32941780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.